Neuphoria Therapeutics Inc.
NEUP
$4.66
-$0.01-0.21%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -21.72% | 15.46% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -64.73% | -58.50% | |||
| Operating Income | 64.73% | 58.50% | |||
| Income Before Tax | -129.51% | 118.40% | |||
| Income Tax Expenses | 0.00% | 0.00% | |||
| Earnings from Continuing Operations | -127.10% | 118.82% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -127.10% | 118.82% | |||
| EBIT | 64.73% | 58.50% | |||
| EBITDA | 69.65% | 60.27% | |||
| EPS Basic | -122.71% | 109.32% | |||
| Normalized Basic EPS | -113.61% | 115.27% | |||
| EPS Diluted | 87.96% | 82.43% | |||
| Normalized Diluted EPS | -113.61% | 115.27% | |||
| Average Basic Shares Outstanding | 19.29% | 101.96% | |||
| Average Diluted Shares Outstanding | 19.29% | 101.96% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||